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Abstract
Objective: To determine the quality of life in cancer patients 
who underwent chemotherapy treatment.
Methods:  A cross-sectional study was conducted from June 
to August 2019. Patients with cancer, who had undergone 
chemotherapy and willing to participate were included in 
this study. The European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire-30 (EORTC 
QLQ–30) questionnaire was used as the measurement tool. 
The patients were grouped into three groups based on the 
cycles of chemotherapy.
Results: Sixty three responders participated in the study. As 
the treatment progressed, there was a signifi cant decrease 
in Global Health Status (GHS) and social function. In 
symptom scales, there was a signifi cant increase in nausea 
and vomiting, pain, and insomnia. 
Conclusions: There was a decrease in the quality of life 
in patients with gynecological cancer who underwent 
chemotherapy in dr. Cipto Mangunkusumo National 
General Hospital. This result should be an evaluation for 
the healthcare provider to implement a holistic approach in 
managing cancer patients.
Keywords: chemotherapy, gynaecological cancer, quality of 
life.
Abstrak
Tujuan: Untuk menilai kualitas hidup pasien kanker yang 
menjalani kemoterapi.
Metode: Penelitian dilakukan dengan metode potong 
lintang, dilakukan dari Juni hingga Agustus 2019. Semua 
pasien dengan kanker yang menjalani kemoterapi dan 
bersedia mengikuti penelitian diikutsertakan dalam 
penelitian ini. Penilaian dilakukan menggunakan kuisioner 
dari The European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-
30) digunakan. Pasien dikelompokkan menjadi 3 kelompok 
berdasarkan siklus kemoterapinya.
Hasil: Terdapat 63 pasien yang berpartisipasi dalam 
penelitian ini. Seiring pengobatan, terdapat penurunan 
signifi kan pada global health status (GHS) dan fungsi sosial. 
Gejala yang meningkat secara signifi kan antara lain mual 
dan muntah, nyeri, dan insomnia.
Kesimpulan: Terdapat penurunan kualitas hidup pada 
pasien kanker ginekologi yang menjalani kemoterapi di 
Rumah Sakit Dr. Cipto Mangunkusumo. Hasil penelitian ini 
menjadi evaluasi untuk penyedia layanan kesehatan agar 
dapat menangani pasien kanker secara holistik.
Kata kunci: kanker ginekologi, kemoterapi, kualitas hidup.
INTRODUCTION
Data from the Global Burden of Cancer 
(Globocan) 2018 estimated a total of 8.622.539 
new cancer cases globally. Cervical cancer ranked 
fourth with an estimation of 549.847 cases, with 
311.365 deaths. Uterine corpus ranked sixth with 
an estimation of 382.069 new cases and 295.414 
cases, while ovarian cancer ranked eighth with 
an estimation of 89.929 new cases and 184.799 
deaths. The estimated incidence of cancer in 
Indonesia in 2018 were 188.231 cases. Cervical, 
ovarian, and uterine corpus were ranked 2nd, 
3rd, and 7th with an estimated incidence of 
32.469, 13.310, and 6.745 cases and accounted 
for 18.279, 7.842, and 2.407 deaths respectively.1
Treatment in cancer patients requires a 
multimodality approach for the diagnosis and 
various methods of treatment, such as surgery, 
chemotherapy, radiation, or palliative treatment. 
Chemotherapy has a crucial role in cancer 
treatment in present days, and it can even increase 
the survivability of patients in some cases that 
proven to be deadly in the past.2,3 The purpose 
of chemotherapy is to eradicate the cancer cells, 
but the normal tissue will also be affected, which 
will cause side effects.2,4 In our department, oral 
prophylactic drugs for nausea such as ranitidine, 
ondansetron, and pain such as mefenamic acid or 
ketorolac are prescribed before chemotherapy.
With the advancement of era, survivability 
is not the sole aspect of cancer treatment 
goal. Patient’s quality of life has become an 
important aspect. Health-related quality of life 
is a multidimensional concept of an individual 
perceived physical, mental, and social health 
status, which is affected by cancer diagnosis 
or treatment,5 measured with the European 
Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire-30 (EORTC 
QLQ-30) questionnaire. This questionnaire will 
include physical, mental, and fi nancial factors.3,6 
EORTC QLQ-30 validation and reliability has been 
proven internationally and has been used in more 
than 9000 studies.7–9 
This study aims to assess the quality of life 
in patients with gynecological cancer in our 
institution who underwent chemotherapy to 
provide a better holistic approach in the treatment 
of gynaecological cancer patients.
METHODS
This was a cross-sectional study to measure the 
quality of life of patients with gynecologic cancer 
who underwent chemotherapy. The study was 
conducted from June to August 2019. Patients 
who were diagnosed with cancer and had 
undergone chemotherapy were included. After 
we obtained the informed consent from patients 
and/or family, we assessed their quality of life. We 
used the EORTC QLQ-30 questionnaire to assess 
the patients' quality of life. The assessment was 
performed on the day after chemotherapy. The 
protocol has been reviewed and approved by our 




Participants were divided into three groups 
based on the number of chemotherapy cycles. 
Group 1 consisted of participants who had 
already undergone 1-2 cycles of chemotherapy, 
group 2 consisted of participants who had 
already undergone 3-4 cycles of chemotherapy, 
and group 3 consisted of participants who had 
already undergone 5 cycles of chemotherapy and 
above. The comparison of the EORTC QLQ-30 
score was analyzed using the analysis of variance 
(ANOVA) and Tukey's honestly signifi cant 
difference test (T-HSD). Statistical analysis was 
done using Statistical Package for Social Sciences 
(SPSS) program.
RESULTS
A total of 63 participants were recruited from 
June until August 2019. The patient’s average 
age was 45.4 ± 12.72 years old. The patient’s 
characteristics were presented in Table 1.
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From the 63 participants, 21 participants fell 
into group 1, 21 participants fell into group 2, 
and 21 participants fell into group 3.  EORTC 
QLQ-30 result's comparison (Table 2) showed a 
signifi cant decrease in Global Health Status (GHS) 
and social function. Symptoms scale showed a 
signifi cant increase in nausea and vomiting, pain, 
and insomnia.
The comparison also made between the study 
group (G1-G3) with normal women reference 
value as stated in study 10 (Table 3). All of the 
EORTC QLQ-30 components showed signifi cant 
differences except dyspnea symptoms.
Table 1. Patient’s Characteristics
Table 2. EORTC QLQ-30 Result
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Table 3. Comparison between Study Group with the Normal Women Reference Value10
DISCUSSION
In this study, a decrease in GHS was shown 
chemotherapy treatment progress. Gradual 
increase of intensity and frequency of side 
effects experienced by patients compromises 
their physic, functional, and social lives. On the 
contrary, a study showed an increased quality of 
life as the treatment progressed.3 A similar result.9 
Social function signifi cantly decreases, and 
the overall low result (<75) on role function and 
emotional function could be caused by cancer 
diagnosis. diagnosis itself. Moreover, the social 
environment will also play a role in the result. 
The shame and stigma associated with cancer 
also became a burden in some patients. In their 
family, some patients felt disheartening with 
overwhelming attention and limitation of activity 
from their family. Some patients who live in 
middle-low class social environments, mocking 
of cancer diagnosis and their appearance also 
have a massive effect on patient functional. 
Alopecia, the common side effect from 
carboplatin and paclitaxel, from carboplatin 
and paclitaxel have an immense effect on this 
functional scale. Symptoms such as pain, fatigue, 
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nausea, insomnia, and fi nancial factors will also 
contribute to the result.
The increase of side effects will directly affect 
the symptoms scale. All of the participants were 
covered by the Badan Penyelenggara Jaminan 
Nasional (BPJS) or The Indonesian National 
Health Insurance. The patient who will undergo 
chemotherapy will be hospitalized for one day. The 
chemotherapy will be administered on that day, 
and non-complicated patients will be discharged 
the next day. Prophylactic treatment for the side 
effects of chemotherapy will be given when he/
she is discharged. Symptomatic medication 
from the BPJS such as antiemetic (ranitidine, 
ondansetron) and pain killer (mefenamic acid 
and ketorolac) will be prescribed on the day 
patient discharged. Most patients felt the side 
effects on the third to fi fth day. This delay can 
be problematic in providing appropriate drugs, 
dosage, and timing of the drug administration, 
which will directly affect the patient's quality 
of life. The National Health Insurance also has 
limitations in treating loss of appetite and 
insomnia, which will signifi cantly affect low-
income patients. The system has scheduled visits 
to the doctor. Early visit only covers emergency 
cases and symptoms such as increasing pain and 
nausea will not be accepted in front of schedule.
A comparison of this study with normal women 
reference value showed a general difference 
in all components of the questionnaire except 
dyspnea.10 These differences demonstrate the 
decrease in cancer patients quality of life right 
after early chemotherapy treatment and as the 
treatment progressed compared with normal 
women reference value. These results imply 
that quality of life has not been recognized as 
the main component in cancer treatment. The 
decline in quality of life in cancer patients who 
underwent treatment in Indonesia should be 
a challenge for health providers, especially in 
Indonesia to implement a holistic approach for 
cancer patients.
This studys limitation is in the population's 
variety, such as types of cancer with different types, 
stages, surgical histories, and chemotherapy 
regimens, which cause a different effect on each 
patient. Also, there might be different perceptions 
and understandings of the questionnaire given, 
although the explanation was made prior to 
answering.
CONCLUSION
Cancer and its treatment will affect entirely 
on patient life. Conventional cancer treatment 
without considering the patient's quality of 
life can hinder the primary purpose of the 
treatment. There was a decline in quality of life 
in cancer patients who underwent treatment in 
our institution. The result is proof that quality of 
life has not been a priority in cancer treatment 
in Indonesia. A holistic approach should be more 
emphasized, especially on the patient who will 
undergo chemotherapy. Further study with a 
specifi c type of cancer, chemotherapy regiment, 
or operation history is needed to establish a 
more specifi c association between side effects of 
chemotherapy with quality of life.
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